{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T04:16:38Z","timestamp":1726719398876},"reference-count":66,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014720","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T12:09:39Z","timestamp":1726661379000},"update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy for advanced and recurrent malignant pleural mesothelioma"],"prefix":"10.1002","volume":"2024","author":[{"given":"Anna Karen","family":"Haugaard","sequence":"additional","affiliation":[{"name":"Department of Oncology; Herlev and Gentofte Hospital, University of Copenhagen; Herlev Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Saude Conde","sequence":"additional","affiliation":[{"name":"Digestive Oncology Department; Institut Jules Bordet, H\u00f4pital Universitaire de Bruxelles; Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Rita","family":"J Maria","sequence":"additional","affiliation":[{"name":"Comprehensive Health Research Centre; Nova Medical School | Faculdade de Ci\u00eancias M\u00e9dicas da Universidade NOVA de Lisboa; Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijna","family":"Vithal Yergolkar","sequence":"additional","affiliation":[{"name":"Naperville Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karsten Juhl","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Cochrane Denmark and Centre for Evidence Based Medicine Odense; University of Southern Denmark; Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Heleno","sequence":"additional","affiliation":[{"name":"Comprehensive Health Research Centre; Nova Medical School | Faculdade de Ci\u00eancias M\u00e9dicas da Universidade NOVA de Lisboa; Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD014720-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"e57132","DOI":"10.1371\/journal.pone.0057132","article-title":"Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers","volume":"8","author":"Akl","year":"2013","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1002\/14651858.CD014720-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/bjc.2015.77","article-title":"The effect of chemotherapy on health-related quality of life in mesothelioma: Results from the SWAMP trial","volume":"112","author":"Arnold D","year":"2015","journal-title":"British Journal of Cancer"},{"issue":"10","key":"10.1002\/14651858.CD014720-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/j.jtho.2020.08.004","article-title":"First-line nivolumab + ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743","volume":"15","author":"Baas","year":"2020","journal-title":"Journal of Thoracic Oncology"},{"issue":"10272","key":"10.1002\/14651858.CD014720-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD014720-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.lungcan.2015.03.005","article-title":"Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales","volume":"88","author":"Beckett","year":"2015","journal-title":"Lung Cancer"},{"issue":"142","key":"10.1002\/14651858.CD014720-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/16000617.0063-2016","article-title":"Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment","volume":"25","author":"Bibby","year":"2016","journal-title":"European Respiratory Review"},{"issue":"5","key":"10.1002\/14651858.CD014720-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the Bio-MAPS cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clinical Lung Cancer"},{"key":"10.1002\/14651858.CD014720-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Buchbinder EI Desai A CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition American Journal of Clinical Oncology: Cancer Clinical Trials 2016 39 1 98 106","DOI":"10.1097\/COC.0000000000000239"},{"issue":"5","key":"10.1002\/14651858.CD014720-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD014720-BIB0010|cit10","unstructured":"Caruana E Nakas A Development of a core outcome set for clinical studies of the invasive management of malignant pleural mesothelioma: the COS-iMeso Initiative Available at www.comet-initiative.org\/Studies\/Details\/1426"},{"issue":"3","key":"10.1002\/14651858.CD014720-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD014720-BIB0012|cit12","unstructured":"Covidence Veritas Health Innovation 2024"},{"issue":"February","key":"10.1002\/14651858.CD014720-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fonc.2020.00187","article-title":"Immunotherapy in malignant pleural mesothelioma","volume":"10","author":"De Gooijer","year":"2020","journal-title":"Frontiers in Oncology"},{"key":"10.1002\/14651858.CD014720-BIB0014|cit14","unstructured":"Deeks JD Higgins JP Altman DG on behalf of the Cochrane Statistical Methods Group Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD014720-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"3","key":"10.1002\/14651858.CD014720-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.21037\/tlcr.2017.05.02","article-title":"Immunotherapy for malignant pleural mesothelioma: current status and future directions","volume":"6","author":"Dozier","year":"2017","journal-title":"Translational Lung Cancer Research"},{"issue":"19","key":"10.1002\/14651858.CD014720-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-18-2860","article-title":"Health-related quality of life impact from adding bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS IFCT-GFPC-0701 phase III trial","volume":"25","author":"Eberst","year":"2019","journal-title":"Clinical Cancer Research"},{"issue":"9","key":"10.1002\/14651858.CD014720-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jclinepi.2013.03.014","article-title":"Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers","volume":"66","author":"Ebrahim","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD014720-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD014720-BIB0020|cit20","unstructured":"European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) Assessment report, EMA\/CHMP\/260350\/2021; April 2021 www.ema.europa.eu\/en\/documents\/variation-report\/opdivo-emea\/h\/c\/ws1881-epar-assessment-report-variation_en.pdf"},{"issue":"4","key":"10.1002\/14651858.CD014720-BIB0021|cit21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013257.pub3","article-title":"Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer","author":"Ferrara","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"21","key":"10.1002\/14651858.CD014720-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014720-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/tcrm.s1603","article-title":"Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma","volume":"4","author":"Goudar","year":"2008","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"10.1002\/14651858.CD014720-BIB0024|cit24","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"issue":"4","key":"10.1002\/14651858.CD014720-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.21037\/tlcr-20-583","article-title":"Controversies in the role of radiotherapy in pleural mesothelioma","volume":"10","author":"Hanna","year":"2021","journal-title":"Translational Lung Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD014720-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncology"},{"issue":"5","key":"10.1002\/14651858.CD014720-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/JTO.0b013e31828353d7","article-title":"Surgery in mesothelioma - where do we go after MARS?","volume":"8","author":"Hiddinga","year":"2013","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD014720-BIB0028|cit28","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD014720-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"850\u20138","DOI":"10.1200\/JCO.2017.75.1644","article-title":"Immune-modified Response Evaluation Criteria In Solid Tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy","volume":"36","author":"Hodi","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014720-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835920962362","article-title":"PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study","volume":"12","author":"Jin","year":"2020","journal-title":"Therapeutic Advances in Medical Oncology"},{"key":"10.1002\/14651858.CD014720-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejrad.2018.02.017","article-title":"Low-dose chest computed tomography screening of subjects exposed to asbestos","volume":"101","author":"Kato","year":"2018","journal-title":"European Journal of Radiology"},{"key":"10.1002\/14651858.CD014720-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"S2213","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial","volume":"24","author":"Lim","year":"2024","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD014720-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835920940927","article-title":"Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis","volume":"12","author":"Liu","year":"2020","journal-title":"Therapeutic Advances in Medical Oncology"},{"key":"10.1002\/14651858.CD014720-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1183\/13993003.02049-2015","article-title":"Defining a standard set of patient-centred outcomes for lung cancer","volume":"48","author":"Mak","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD014720-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD014720-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases - elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Current Opinion in Immunology"},{"key":"10.1002\/14651858.CD014720-BIB0037|cit37","unstructured":"National Cancer Institute (NCI) Division of Cancer Treatment & Diagnosis Cancer Therapy Evaluation Program (CTEP) - Common Terminology Criteria for Adverse Events (CTCAE) Available at: ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"10.1002\/14651858.CD014720-BIB0038|cit38","unstructured":"National Comprehensive Cancer Network NCCN Guidelines for Malignant Pleural Mesothelioma Version 1- 2022 https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1512"},{"key":"10.1002\/14651858.CD014720-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"3936\u201343","DOI":"10.1158\/1078-0432.CCR-13-0895","article-title":"Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements","volume":"19","author":"Nishino","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD014720-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"e076754","DOI":"10.1136\/bmj-2023-076754","article-title":"ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis","volume":"383","author":"Page","year":"2023","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014720-BIB0041|cit41","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"7","key":"10.1002\/14651858.CD014720-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: Results of the international expanded access program","volume":"3","author":"Santoro","year":"2008","journal-title":"Journal of Thoracic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD014720-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncology"},{"issue":"6","key":"10.1002\/14651858.CD014720-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"Scherpereel","year":"2020","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD014720-BIB0045|cit45","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD014720-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"e143\u201352","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD014720-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s11033-019-04715-9","article-title":"Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma","volume":"46","author":"Sobhani","year":"2019","journal-title":"Molecular Biology Reports"},{"key":"10.1002\/14651858.CD014720-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014720-BIB0049|cit49","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"7","key":"10.1002\/14651858.CD014720-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-018-1156-x","article-title":"Is there a role for immunotherapy in malignant pleural mesothelioma?","volume":"35","author":"Tartarone","year":"2018","journal-title":"Medical Oncology"},{"key":"10.1002\/14651858.CD014720-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"205\u201316","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"issue":"9","key":"10.1002\/14651858.CD014720-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S1470-2045(17)30511-9","article-title":"CTLA-4 blockade in mesothelioma: ineffective or reason for optimism?","volume":"18","author":"Thomas","year":"2017","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD014720-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","article-title":"Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness","volume":"13","author":"Tufanaru","year":"2015","journal-title":"International Journal of Evidence-Based Healthcare"},{"key":"10.1002\/14651858.CD014720-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cllc.2020.11.009","article-title":"CheckMate 743: a glimmer of hope for malignant pleural mesothelioma","volume":"2","author":"Uprety","year":"2021","journal-title":"Clinical Lung Cancer"},{"issue":"14","key":"10.1002\/14651858.CD014720-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014720-BIB0056|cit56","doi-asserted-by":"crossref","unstructured":"Wei SC Duffy CR Allison JP Fundamental mechanisms of immune checkpoint blockade therapy Cancer Discovery 2018 8 9 1069 86","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"10.1002\/14651858.CD014720-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"7412\u201320","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"10.1002\/14651858.CD014720-BIB0058|cit58","first-page":"502","article-title":"FDA approves nivolumab plus ipilimumab for previously untreated unresectable malignant pleural mesothelioma","volume":"34","author":"Wright","year":"2020","journal-title":"Oncology (Williston Park, N.Y.)"},{"issue":"1","key":"10.1002\/14651858.CD014720-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.thorsurg.2012.10.002","article-title":"Surgical management of malignant pleural mesothelioma","volume":"23","author":"Yanagawa","year":"2013","journal-title":"Thoracic Surgery Clinics"},{"key":"10.1002\/14651858.CD014720-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835920971421","article-title":"Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma","volume":"12","author":"Yang","year":"2020","journal-title":"Therapeutic Advances in Medical Oncology"},{"key":"10.1002\/14651858.CD014720-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","article-title":"Beta blockade during and after myocardial infarction: an overview of the randomized trials","volume":"27","author":"Yusuf","year":"1985","journal-title":"Progress in Cardiovascular Diseases"},{"issue":"31","key":"10.1002\/14651858.CD014720-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1200\/JCO.2008.19.7491","article-title":"Defining best supportive care","volume":"26","author":"Zafar","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"10026","key":"10.1002\/14651858.CD014720-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD014720-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"e2120360","DOI":"10.1001\/jamanetworkopen.2021.20360","article-title":"Assessment of global trends in the diagnosis of mesothelioma from 1990 to 2017","volume":"4","author":"Zhai","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1002\/14651858.CD014720-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.cllc.2020.05.012","article-title":"PD-1\/PD-L1 checkpoint inhibitor immunotherapy for malignant pleural mesothelioma: case series and literature review","volume":"3","author":"Zhou","year":"2021","journal-title":"Clinical Lung Cancer"},{"key":"10.1002\/14651858.CD014720-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"e101441","DOI":"10.1016\/j.ssmph.2023.101441","article-title":"Global, regional, and national trends in mesothelioma burden from 1990 to 2019 and the predictions for the next two decades","volume":"23","author":"Zhu","year":"2023","journal-title":"SSM Population Health"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T12:09:54Z","timestamp":1726661394000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014720"}},"subtitle":[],"editor":[{"name":"Cochrane Lung Cancer Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014720","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]}}}